We claim:

1. A compound of Formula I or a salt thereof,



I

wherein;

R_1 and R_2 are independently selected from the group consisting of: $-CH_3$, $-CH_2CH_3$, $-CH_2OH$, $-CH_2OR'$, $-CHO$, $-CO_2H$, and $-CO_2R'$;

R_3 and R_4 are independently selected from the group consisting of: H, $-CH_3$, $-CH_2CH_3$, $-CH_2OH$, $-CH_2OR'$, $-CHO$, $-CO_2H$, and $-CO_2R'$;

Q is a carbon skeleton selected from the group consisting of: $-CH_2-$, $-CY_1Y_2-$, $-CH_2CH_2-$, $-CH=CH-$, $-CY_1Y_2CY_3Y_4-$, $-CH_2CH_2CH_2-$, $-CH=CHCH_2-$, $-CH=CHCY_1Y_2-$, and $-CY_1Y_2CY_3Y_4CY_5Y_6-$; where Y_1, Y_2, Y_3, Y_4, Y_5, and Y_6 are independently selected from the group consisting of: H, F, Br, Cl, I, OH, OR', and SH; or any one group of Y_1/Y_2, Y_3/Y_4, and Y_5/Y_6 may be =O; or Y_1/Y_3 may form an epoxide; and, at least one of Y_1, Y_2, Y_3, Y_4, Y_5 and Y_6 when present, is not H;

X_1, X_2, X_3, and X_4 are independently selected from the group consisting of: H, R, OH, -OR, $-CO_2H$, $-CO_2R'$, F, Br, Cl, I, -CN, $-SO_3H$, $-OSO_3H$, NO_2, NH_2, -NHR, and $-NR_2$; where R is a linear, branched, or cyclic, saturated or unsaturated one to ten carbon alkyl group that is unsubstituted or is substituted with one or more of: OH, =O, SH, F, Br, Cl, I, NH_2, -NHR', $-NR'_2$, NO_2, $-CO_2H$, $-CO_2R'$, and epoxide;

and R' is a linear, branched, or cyclic, saturated or unsaturated one to ten carbon alkyl group that is unsubstituted or substituted with one or more of: OH, =O, SH, F, Br, Cl, I, NH_2, -NHR", $-NR"_2$, NO_2 and $-CO_2H$ where R" is a linear, branched, or cyclic, saturated or unsaturated one to ten carbon alkyl group;

providing that the compound does not have the precise structure of pelorol or any one of the group of structures consisting of:


Me
Me
H
H
Me
Me
Me


Me
Me
H
H
Me
Me


Me
Me
H
H
MeO
MeO
Me
Me


Me
Me
H
H
Me
Me
Me


Me
Me
Me
Me
Me

and


Me
Me

2. The compound of claim 1, wherein $Y_1 - Y_6$ are independently selected from H, F, Br, Cl and I.

3. The compound of claim 1, wherein Q is $-CH_2-$, $-CH_2CH_2-$, $-CH=CH-$, $-CH_2-CH_2CH_2-$, or $-CH=CHCH_2-$.

4. The compound of claim 1, 2, or 3, wherein the carbon skeleton of Q is saturated.

5. The compound of any one of claims 1-4, wherein the carbon skeleton of Q consists of one or two carbon atoms.

6. The compound of any one of claims 1-5, wherein R_1 is methyl, ethyl, $-CH_2OH$, or $-CH_2OR'$.

7. The compound of any one of claims 1-6, wherein R_2 is methyl, ethyl, $-CH_2OH$, or $-CH_2OR'$.

8. The compound of any one of claims 1-7, wherein R' in R_1 is limited to methyl, ethyl, propyl or butyl.

9. The compound of any one of claims 1-8, wherein R' in R_2 is limited to methyl, ethyl, propyl or butyl.

10. The compound of claim 8 or 9, wherein R' is limited to methyl or ethyl.

11. The compound of any one of claims 1-10, wherein X_1 is H, OH, R, OR, $-CONH_2$, -CONHR', or $-COR'_2$.

12. The comopund of any one of claims 1-11, wherein X_2 is H, OH, R, OR, $-CONH_2$, -CONHR', or $-COR'_2$.

13. The compound of any one of claims 1-12, wherein X_3 is H, OH, R, OR, -$CONH_2$, -CONHR', or -COR'_2.

14. The compound of any one of claims 1-13, wherein R and R' in one or more of X_1, X_2, and X_3 are limited to methyl, ethyl, propyl and butyl.

15. The compound of any one of claims 1-10, wherein X_1 is H, OH, or –OCH_3.

16. The compound of any one of claims 1-10 and 15, wherein X_2 is H, OH, or OCH_3.

17. The compound of any one of claims 1-10 and 15, wherein X_2 is H, OCH_3, or -$NHOCH_3$.

18. The compound of any one of claims 1-10, 15, 16, and 17, wherein X_3 is H, OH, or OCH_3.

19. The compound of any one of claims 1-18, wherein X_4 is H, R, OH, OR, CO_2H or CO_2R'.

20. The compound of any one of claims 1-19, wherein R and R' in X_4 are limited to methyl, ethyl, propyl or butyl.

21. The compound of any one of claims 1-18, wherein X_4 is H, R, OH, OCH_3, -CO_2H or –CO_2CH_3.

22. The compound of claim 1, selected from: homopelorol, dimethoxypelorol, PNSR-4A, PNSR-15A, PNSR-16A, PNSR-17A and PNSR-18A.

23. The compound of any one of claims 1-22, having the configuration S, R, R, S at C-5, C-8, C-9 and C-10 respectively.

24. The compound of any one of claims 1-22, having the configuration R, S, S, R at C-5, C-8, C-9 and C-10 respectively.

25. The compound of any one of claims 1-24, for use as a modulator of SHIP 1 activity.

26. The compound of claim 25, wherein the compound is an agonist of SHIP 1 activity.

27. Use of a compound of any one of claims 1-26 for preparation of a medicament for the treatment or prevention of an inflammatory, neoplastic, hematopoietic or immune disorder or condition.

28. A method of making a compound of Formula IA in which $R_1 - R_4$, X_1, X_3 and X_4 are as defined in claim 1,



IA

wherein, L' is a C_1 – C_4 saturated or unsaturated alkyl linking group; and A is an activating group; comprising reacting a compound of Formula IIA or IIB:



IIA



IIB

in which L is absent or is a C_1 – C_3 saturated or unsaturated alkyl linking group and E and E' are electrophilic reactive groups; with a compound of Formula III



III

in which Nu is a group that renders the compound of Formula III nucleophilic at Nu, followed by optional reduction and by hydrolysis, to produce a compound of Formula IV



IV

and condensing the compound of Formula IV to produce a compound of Formula IA.

29. The method of claim 28, wherein the compounds of Formula IIA and IIB have the structures:



IIA



IIB

30. The method of claim 29, wherein the compounds of Formula IIA and IIB have the structures



IIA



IIB

31. The method of any one of claims 28-30, wherein the compound of Formula IIA or IIB is sclareolide or is derived from sclareolide.

32. The method of any one of claims 28-31, wherein Nu is lithium.

33. The method of any one of claims 28-32, wherein A is OCH_3 or $-NHOCH_3$.

34. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of Formula I or pharmaceutically acceptable salts thereof,



I

wherein;

R_1 and R_2 are independently selected from the group consisting of: $-CH_3$, $-CH_2CH_3$, $-CH_2OH$, $-CH_2OR'$, -CHO, $-CO_2H$, and $-CO_2R'$;

R_3 and R_4 are independently selected from the group consisting of: H, $-CH_3$, $-CH_2CH_3$, $-CH_2OH$, $-CH_2OR'$, -CHO, $-CO_2H$, and $-CO_2R'$;

Q is a carbon skeleton selected from the group consisting of: $-CH_2-$, $-CY_1Y_2-$, $-CH_2CH_2-$, -CH=CH-, $-CY_1Y_2CY_3Y_4-$, $-CH_2CH_2CH_2-$, $-CH=CHCH_2-$, $-CH=CHCY_1Y_2-$, and $-CY_1Y_2CY_3Y_4CY_5Y_6-$; where Y_1, Y_2, Y_3, Y_4, Y_5, and Y_6 are independently selected from the group consisting of: H, F, Br, Cl, I, OH, OR', and SH; or any one group of Y_1/Y_2, Y_3/Y_4, and Y_5/Y_6 may be =O; or Y_1/Y_3 may form an epoxide; and, at least one of Y_1, Y_2, Y_3, Y_4, Y_5 and Y_6 when present, is not H;

X_1, X_2, X_3, and X_4 are independently selected from the group consisting of: H, R, OH, -OR, $-CO_2H$, $-CO_2R'$, F, Br, Cl, I, -CN, $-SO_3H$, $-OSO_3H$, NO_2, NH_2, -NHR, and $-NR_2$; where R is a linear, branched, or cyclic, saturated or unsaturated one to ten carbon alkyl group that is unsubstituted or is substituted with one or more of: OH, =O, SH, F, Br, Cl, I, NH_2, -NHR', $-NR'_2$, NO_2, $-CO_2H$, $-CO_2R'$, and epoxide;

and R' is a linear, branched, or cyclic, saturated or unsaturated one to ten carbon alkyl group that is unsubstituted or substituted with one or more of: OH, =O, SH, F, Br, Cl, I, NH_2, -NHR", $-NR"_2$, NO_2 and $-CO_2H$ where R" is a linear, branched, or cyclic, saturated or unsaturated one to ten carbon alkyl group.

35. The pharmaceutical composition of claim 34, wherein the one or more compounds of Formula I is not solely pelorol.

36. The pharmaceutical composition of claim 34, comprising pelorol.

37. The pharmaceutical composition of claim 34, 35, or 36, comprising a compound according to any one of claims 1-26.

38. A method of prophylaxis or treatment of an immune, hematopoietic, inflammatory or neoplastic disorder or condition comprising administering to a patient in need of said prophylaxsis or treatment, an effective amount of a pharmaceutical composition according to any one of claims 34-37.